Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Factor

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|February 24, 2001
Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trialS A Factor, J H Friedman, M C Lannon, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 1, 1989
Efficacy of sinemet CR4 in subgroups of patients with Parkinson's diseaseS A Factor, J R Sanchez-Ramos, W J Weiner, et al.
Journal of the Neurological Sciences|March 1, 1994
Platelet morphology in Parkinson's disease: an electron microscopic studyS A Factor, E Ortof, M P Dentinger, et al.
Parkinsonism & Related Disorders|January 1, 1997
Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulnessR A Hauser, T A Zesiewicz, S A Factor, et al.
European Journal of Neurology|August 13, 2011
An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson's diseaseE M Hill-Burns, T H Hamza, C P Zabetian, et al.
Clinical Neuropharmacology|October 5, 2001
Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's diseaseS A Factor, E S Molho, P J Feustel, et al.
Neurology|November 23, 2000
An extended 5'-tau susceptibility haplotype in progressive supranuclear palsyJ J Higgins, L I Golbe, A De Biase, et al.
Neurology|December 1, 2010
Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of NeurologyE M Cheng, S Tonn, R Swain-Eng, et al.
Neurology|January 1, 1993
Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's diseaseW J Weiner, S A Factor, J R Sanchez-Ramos, et al.
Journal of Neural Transmission. Supplementum|January 1, 1995
The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's diseaseE S Molho, S A Factor, W J Weiner, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Movement Disorders : Official Journal of the Movement Disorder Society|February 24, 2001
Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trialS A Factor, J H Friedman, M C Lannon, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 1, 1989
Efficacy of sinemet CR4 in subgroups of patients with Parkinson's diseaseS A Factor, J R Sanchez-Ramos, W J Weiner, et al.
Journal of the Neurological Sciences|March 1, 1994
Platelet morphology in Parkinson's disease: an electron microscopic studyS A Factor, E Ortof, M P Dentinger, et al.
Parkinsonism & Related Disorders|January 1, 1997
Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulnessR A Hauser, T A Zesiewicz, S A Factor, et al.
European Journal of Neurology|August 13, 2011
An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson's diseaseE M Hill-Burns, T H Hamza, C P Zabetian, et al.
Clinical Neuropharmacology|October 5, 2001
Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's diseaseS A Factor, E S Molho, P J Feustel, et al.
Neurology|November 23, 2000
An extended 5'-tau susceptibility haplotype in progressive supranuclear palsyJ J Higgins, L I Golbe, A De Biase, et al.
Neurology|December 1, 2010
Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of NeurologyE M Cheng, S Tonn, R Swain-Eng, et al.
Neurology|January 1, 1993
Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's diseaseW J Weiner, S A Factor, J R Sanchez-Ramos, et al.
Journal of Neural Transmission. Supplementum|January 1, 1995
The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's diseaseE S Molho, S A Factor, W J Weiner, et al.
Pageof 8